Cargando…

Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy

We report the case of a 53-year-old woman with severe chronic inflammatory demyelinating polyneuropathy (CIDP) who developed progressive tetraplegia with respiratory failure despite receiving a standard dose of intravenous immunoglobulin therapy (IVIg), steroid pulse therapy, plasma exchange, and cy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seino, Yusuke, Nakamura, Takumi, Hirohata, Mie, Kawarabayashi, Takeshi, Okushima, Toshimi, Shoji, Mikio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465009/ https://www.ncbi.nlm.nih.gov/pubmed/30449785 http://dx.doi.org/10.2169/internalmedicine.1723-18

Ejemplares similares

Perineuritis Successfully Treated with Early Aggressive Immunotherapy
por: Nakamura, Takumi, et al.
Publicado: (2019)

Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy
por: Talaei, M., et al.
Publicado: (2021)

Aging and APOE‐ε4 are determinative factors of plasma Aβ42 levels
por: Nakamura, Takumi, et al.
Publicado: (2018)

Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins
por: Mahdi-Rogers, Mohamed, et al.
Publicado: (2010)

Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy
por: Khoo, Anthony, et al.
Publicado: (2019)

Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study
por: Cornblath, David R., et al.
Publicado: (2023)

Quantitative Measurement of Cerebrospinal Fluid Amyloid-β Species by Mass Spectrometry
por: Seino, Yusuke, et al.
Publicado: (2021)

Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy
por: Goyal, Namita A., et al.
Publicado: (2021)

Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins
por: Ritter, Christian, et al.
Publicado: (2015)

Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada
por: Blackhouse, Gord, et al.
Publicado: (2010)

Two comparative assessments of intravenous immunoglobulin therapy switching patterns in the treatment of chronic inflammatory demyelinating polyneuropathy in the US
por: Guptill, Jeffrey T, et al.
Publicado: (2019)

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study
por: Mielke, Orell, et al.
Publicado: (2019)

Standardized Tapering off Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy
por: Markvardsen, Lars K., et al.
Publicado: (2023)

Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: A Historical Perspective
por: Cocito, Dario, et al.
Publicado: (2023)

Oral Immunization with Soybean Storage Protein Containing Amyloid-β 4–10 Prevents Spatial Learning Decline
por: Kawarabayashi, Takeshi, et al.
Publicado: (2019)

Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study
por: Adrichem, M. E., et al.
Publicado: (2019)

Subcutaneous Immunoglobulin in Infantile Chronic Inflammatory Demyelinating Polyneuropathy: A Case Report
por: Cianci, Paola, et al.
Publicado: (2019)

Effectiveness of Medium-Dose Intravenous Immunoglobulin (1 g/kg) in the Treatment of Kawasaki Disease
por: Yeo, Joong-Seok, et al.
Publicado: (2010)

Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial
por: Kuwabara, Satoshi, et al.
Publicado: (2017)

Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy
por: Klehmet, Juliane, et al.
Publicado: (2023)

Chronic Inflammatory Demyelinating Polyneuropathy Variant with Creatine-Kinase Elevation and Vanishing Effect of Immunoglobulins
por: Finsterer, Josef, et al.
Publicado: (2017)

Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy
por: Adrichem, Max E., et al.
Publicado: (2022)

Spastic Paraplegia with Paget's Disease of Bone due to a VCP Gene Mutation
por: Nakamura, Takumi, et al.
Publicado: (2020)

High-dose immunoglobulin-dependent chronic demyelinating inflammatory polyneuropathy successfully managed with subcutaneous immunoglobulin using pharmacokinetic analysis
por: Hiya, Satomi, et al.
Publicado: (2022)

Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy
por: Tortorici, Michael A., et al.
Publicado: (2021)

Anti-LGI4 Antibody Is a Novel Juxtaparanodal Autoantibody for Chronic Inflammatory Demyelinating Polyneuropathy
por: Zhang, Xu, et al.
Publicado: (2023)

A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States
por: Mallick, Rajiv, et al.
Publicado: (2023)

Depression with Chronic Inflammatory Demyelinating Polyneuropathy
por: Marwale, Arun, et al.
Publicado: (2018)

Alternatives to intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy
por: Castle, Dan, et al.
Publicado: (2019)

Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy
por: Rajabally, Yusuf A., et al.
Publicado: (2018)

CogEvo, a cognitive function balancer, is a sensitive and easy psychiatric test battery for age‐related cognitive decline
por: Ichii, Sadanobu, et al.
Publicado: (2019)

IgG4-related hypothalamo-hypophysitis
por: Urushida, Yuki, et al.
Publicado: (2021)

Genetic biomarkers for intravenous immunoglobulin response in chronic inflammatory demyelinating polyradiculoneuropathy
por: Kuitwaard, Krista, et al.
Publicado: (2021)

A Case of Paraneoplastic Demyelinating Motor Polyneuropathy
por: Mostoufizadeh, Sohrab, et al.
Publicado: (2012)

Tailoring of therapy for chronic inflammatory demyelinating polyneuropathy
por: Rajabally, Yusuf A.
Publicado: (2015)

Challenges in the diagnosis of chronic inflammatory demyelinating polyneuropathy
por: Allen, Jeffrey A., et al.
Publicado: (2018)

The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy
por: Bril, Vera, et al.
Publicado: (2016)

Anesthetic management of a patient with chronic inflammatory demyelinating polyneuropathy by combination of total intravenous and regional anesthesia
por: Takekawa, Daiki, et al.
Publicado: (2019)

Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis
por: Perraudin, Clémence, et al.
Publicado: (2020)

Dose Adjustment of Subcutaneous IgG in Chronic Inflammatory Demyelinating Polyneuropathy
por: Alsolaihim, Alanood, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l1hb20n4r2e9r3h2ijqg543msk